Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ebos GroupNZSE:EBO -1.69%80 EV-to-FCF is 25.27 as of Jul. 21, 2026, which is 14% below its 10-year median of 29.27. GuruFocus rates NZSE:EBO with a GF Score™ of 80/100 and a GF Value™ of NZ$39.94 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 72 Medical Distribution companies, Ebos Group ranks worse than 65.28% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ebos Group's Enterprise Value is NZ$6,323 Mil.
Ebos Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NZ$250 Mil. Therefore, Ebos Group's EV-to-FCF for today is 25.27.
The historical rank and industry rank for Ebos Group's EV-to-FCF or its related term are showing as below:
NZSE:EBO'
s EV-to-FCF Range Over the Past 10 Years
Min: 12.67 Med: 29.27 Max: 53.03
Current: 25.73
During the past 13 years, the highest EV-to-FCF of Ebos Group was 53.03. The lowest was 12.67. And the median was 29.27.
NZSE:EBO's EV-to-FCF is ranked worse than 65.28% of 72
companies
in the Medical Distribution industry
Industry Median: 17.28
vs NZSE:EBO: 25.73
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ebos Group's share price for today is NZ$22.10.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ebos Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NZ$1.248.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ebos Group EV-to-FCF Related Terms
Ebos Group EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Ebos Group's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Ebos Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group EV-to-FCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Ebos Group's EV-to-FCF falls into.
Ebos Group's current Enterprise Value is NZ$6,323 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ebos Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NZ$250 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ebos Group (NZSE:EBO) has a EV-to-FCF of 25.27 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ebos Group and its competitors. This is 14% below median its historical median of 29.27. Over the past decade, Ebos Group's EV-to-FCF has ranged from 12.67 to 53.03. According to the industry distribution chart, Ebos Group ranks #47 out of 72 companies in the Medical Distribution industry, placing it in the top 65.3%.
Is Ebos Group's EV-to-FCF too high?
Ebos Group's current EV-to-FCF of 25.27 is 14% below median its 10-year median of 29.27. Over the past 10 years, this metric has ranged from a low of 12.67 to a high of 53.03. The Medical Distribution industry median EV-to-FCF is 17.28. Ebos Group's value of 25.27 is 46.2% above this industry median. Based on the distribution chart, Ebos Group ranks #47 out of 72 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Ebos Group has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's EV-to-FCF compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #47 out of 72 companies for EV-to-FCF. This places Ebos Group in the lower half of its industry. The industry median EV-to-FCF is 17.28. Ebos Group's value of 25.27 is 46.2% above this benchmark. Historically, Ebos Group's own EV-to-FCF has ranged from 12.67 to 53.03 over the past decade. While the company's 10-year median is 29.27 vs. the industry median of 17.28, Ebos Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Distribution company?
The median EV-to-FCF among Medical Distribution companies is 17.28, based on 72 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current EV-to-FCF of 25.27 is 46.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ebos Group and its competitors. For the Medical Distribution industry, the median EV-to-FCF is 17.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current EV-to-FCF is 25.27, which is 14% below median its own 10-year median of 29.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (NZSE:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is NZ$39.94, compared to a current price of NZ$22.10 — trading 44.7% below its estimated fair value. The current EV-to-FCF is 25.27, which is 14% below median its 10-year median of 29.27 and 46.2% above the Medical Distribution industry median of 17.28. Ebos Group's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Ebos Group (NZSE:EBO), the current EV-to-FCF is 25.27 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (NZSE:EBO) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of NZ$22.10 is trading 44.7% below its estimated GF Value™ of NZ$39.94.
GuruFocus considers Ebos Group to be Significantly Undervalued.
Key valuation signals for NZSE:EBO:
EV-to-FCF: 25.27 (14% below median its 10-year median of 29.27)
GF Value™: NZ$39.94 vs. price of NZ$22.10 (44.7% below fair value)
Industry Position: 46.2% above the Medical Distribution median (#47 of 72)
No single metric tells the full story. See the NZSE:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
80GF Score
Get the complete analysis for NZSE:EBO
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:EBO has been successfully added to your 
